To date, the French-American surgical robot maker said 50 patients in Europe underwent Maestro-assisted surgery. These took place in a clinical trial led by Dr. Guy-Bernard Cadière in Brussels, Belgium.
The company designed Maestro to support surgeons in soft tissue surgical procedures, acting as a robotic surgical assistant. Moon Surgical’s small, adaptable system can integrate into existing clinical workflows. It features capabilities that bolster operating room efficiency and allow for alternative labor models.
Maestro’s design specifically aims to augment the precision and control of laparoscopic surgery. This supports high-volume surgeons performing procedures like cholecystectomy and hernia repairs, along with complex multi-quadrant procedures.
“This new milestone is a testament to our team’s hard work and dedication, and attests to the effective ramp-up of our manufacturing and quality operations,” said Anne Osdoit, CEO of Moon Surgical. “With the Maestro System, we aim to empower surgeons to perform laparoscopy with greater ease, precision, and control, improving patient outcomes and enhancing the overall surgical experience.”
Moon Surgical, which has locations in Paris and San Francisco, received FDA 510(k) clearance for Maestro in December.
In June 2022, Moon Surgical completed a $31.3 million Series A fundraising. Osdoit said the company aims to make Maestro capable of use in any laparoscopy in any operating room. This could revolutionize minimally invasive surgery through collaborative and adaptive robotics.
